1. [VEGF antibodies as therapy for retinopathy of prematurity].
- Author
-
Oberacher-Velten IM and Helbig H
- Subjects
- Angiogenesis Inhibitors adverse effects, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized, Bevacizumab, Combined Modality Therapy, Diseases in Twins classification, Diseases in Twins diagnosis, Diseases in Twins drug therapy, Diseases in Twins physiopathology, Female, Humans, Infant, Extremely Low Birth Weight, Infant, Newborn, Intravitreal Injections, Laser Coagulation, Male, Off-Label Use, Retinopathy of Prematurity classification, Retinopathy of Prematurity diagnosis, Retinopathy of Prematurity physiopathology, Vascular Endothelial Growth Factor A physiology, Angiogenesis Inhibitors administration & dosage, Antibodies, Monoclonal administration & dosage, Retinopathy of Prematurity drug therapy, Vascular Endothelial Growth Factor A antagonists & inhibitors
- Abstract
Retinopathy of prematurity (ROP) is one of the three leading causes of legal blindness in childhood in the developed countries. Improved neonatal care has resulted in the increased survival of extremely immature infants at high risk to develop ROP. Current treatment for ROP with laser may prevent blindness by causing involution of pathological vessels and thus inhibit the development of retinal detachment. But this coagulation of the avascular retina is a destructive therapy and does not otherwise ameliorate retinal development. Recent reports have described vascular endothelial growth factor antibodies as therapy for ROP. This article reports our own experience with this new therapy and gives an overview of the recent literature., (© Georg Thieme Verlag KG Stuttgart · New York.)
- Published
- 2010
- Full Text
- View/download PDF